Pharmacologic and clinical considerations of phosphodiesterase type 5 inhibitors and β-adrenergic receptor type 3 agonists for lower urinary tract symptoms and benign prostatic hyperplasia
- DOI
- 10.1080/17425255.2026.2725917
- Published
- 2026-08-03
- Container
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1080/17425255.2026.2725917,
title = {Pharmacologic and clinical considerations of phosphodiesterase type 5 inhibitors and β-adrenergic receptor type 3 agonists for lower urinary tract symptoms and benign prostatic hyperplasia},
author = {Eviatar Fields and Dean Elterman and Naeem Bhojani and Jennifer Polo and Bilal Chughtai},
year = {2026},
journal = {Expert Opinion on Drug Metabolism \& Toxicology},
doi = {10.1080/17425255.2026.2725917},
url = {https://doi.org/10.1080/17425255.2026.2725917}
}RIS
TY - JOUR TI - Pharmacologic and clinical considerations of phosphodiesterase type 5 inhibitors and β-adrenergic receptor type 3 agonists for lower urinary tract symptoms and benign prostatic hyperplasia AU - Eviatar Fields AU - Dean Elterman AU - Naeem Bhojani AU - Jennifer Polo AU - Bilal Chughtai PY - 2026 JO - Expert Opinion on Drug Metabolism & Toxicology DO - 10.1080/17425255.2026.2725917 UR - https://doi.org/10.1080/17425255.2026.2725917 ER -
APA
Fields, E., Elterman, D., Bhojani, N., Polo, J., & Chughtai, B. (2026). Pharmacologic and clinical considerations of phosphodiesterase type 5 inhibitors and β-adrenergic receptor type 3 agonists for lower urinary tract symptoms and benign prostatic hyperplasia. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1080/17425255.2026.2725917
Source records
- crossref · retrieved 2026-09-26T01:34:22.066Z